Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boeing Co (BA) vs ClearPoint Neuro Inc (CLPT) Price & Performance

ClearPoint Neuro IncTrade

Price performance (Past 24H)

Key statistics

Boeing Co vs ClearPoint Neuro Inc — how do they compare? Boeing Co trades at $233.15 (market cap $183.99B), while ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M). The key difference: Boeing Co is far larger — about 414.3× ClearPoint Neuro Inc's market cap, and Boeing Co pays a 0.03% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.

BACLPT
Market Cap
$183.99B$444.14M
Volume
7,591,579
Sector
IndustrialsHealth
52-Week High
$252.15$29.60
52-Week Low
$179.12$8.66
Enterprise Value
$209.87B$478.72M
Dividend Yield
0.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boeing Co

Boeing (BA) trades at $234.42, up 0.96% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported revenue of $89.46 billion in 2025, turning a net profit of $2.24 billion after years of losses, though margins remain thin. Recent news highlights a strategic deal with Archer Aviation, transferring three subsidiaries for a 19.75% stake, potentially enhancing Boeing's position in autonomous flight technology.

The outlook is cautiously optimistic, with a consensus price target of $284 offering ~21% upside, but risks include high debt, regulatory scrutiny from FAA inspections, and volatile cash flows. Investors should weigh the recovery in commercial aerospace against execution challenges and macroeconomic headwinds.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.

The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boeing Co

The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.

Read more on BA

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT